PLUS1
0.76
0.0027 (0.36%)
0.0027 (0.36%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Acorda Therapeutics Inc | ACOR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.0073 | 0.97% | 0.7573 | 0.7416 | 0.77 | 0.766 | 0.75 | 00:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.7609 | 0.78 | 0.0191 | 2.45% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 4,672 | 2,137,077 | $ 0.7585076 | $ 1,620,989 | 2,124,143 | 0.7001 - 9.32 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:34:18 | formt | 217 | $ 0.76 | USD |
Acorda Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 36.34M | 47.98M | 46.86M | $ 192.41M | $ - | -5.75 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | 2.40% |
Acorda Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/22/2020 | 16:11 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) |
| 5/11/2020 | 15:43 | Edgar (US Regulatory) | Confidential Treatment Order (ct Order) |
| 5/11/2020 | 15:06 | Edgar (US Regulatory) | Confidential Treatment Order (ct Order) |
| 5/08/2020 | 17:19 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 5/06/2020 | 19:23 | PR Newswire (US) | DexCom & Domino's Pizza Set to Join S&P 500; Salesforce.com.. |
| 5/05/2020 | 16:03 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 5/05/2020 | 16:00 | Business Wire | Acorda Reports First Quarter 2020 Financial Results and.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ACOR Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.77 | 0.83 | 0.73 | 0.7595344 | 1,626,755 | -0.0127 | -1.65% |
| 1 Month | 0.815 | 0.883 | 0.7029 | 0.7755118 | 2,404,759 | -0.0577 | -7.08% |
| 3 Months | 0.9095 | 1.3711 | 0.7001 | 0.8788666 | 1,608,003 | -0.1522 | -16.73% |
| 6 Months | 1.83 | 2.78 | 0.7001 | 1.62 | 2,114,819 | -1.07 | -58.62% |
| 1 Year | 9.32 | 9.32 | 0.7001 | 2.43 | 1,821,075 | -8.56 | -91.87% |
| 3 Years | 15.25 | 36.35 | 0.7001 | 10.23 | 1,105,680 | -14.49 | -95.03% |
| 5 Years | 30.49 | 43.63 | 0.7001 | 14.90 | 924,398 | -29.73 | -97.52% |
Acorda Therapeutics Description
| Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States. |
